Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 1.00 |
| ▸ | MAOB | P27338 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.74 |
| ▸ | CDK9 | P50750 | 1/20 | 0.74 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.74 |
| ▸ | CASP3 | P42574 | 2/20 | 0.69 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 6/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.66 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8993463 | 0.91 | MAOA (0.83) | MAOAMAOBSMN1; SMN2CASP3SENP7 | |
| SCHEMBL11059378 | 0.89 | SMN1; SMN2 (0.94) | MAOAMAOBSMN1; SMN2TP53EPHX1 | |
| Diphenylurea SCHEMBL133103 | 0.86 | SMN1; SMN2 (1.00) | MAOAMAOBSMN1; SMN2TP53EPHX1 | |
| SCHEMBL11051606 | 0.84 | MAOA (0.72) | MAOAMAOBSMN1; SMN2TP53CASP3 | |
| Diphenylurea SCHEMBL29392345 | 0.84 | SMN1; SMN2 (0.94) | MAOAMAOBSMN1; SMN2TP53EPHX1 | |
| Diphenylurea SCHEMBL28431956 | 0.84 | SMN1; SMN2 (0.94) | MAOAMAOBSMN1; SMN2TP53EPHX1 | |
| Diphenylurea SCHEMBL3037927 | 0.84 | SMN1; SMN2 (0.94) | MAOAMAOBSMN1; SMN2TP53EPHX1 | |
| Diphenylurea SCHEMBL30786615 | 0.84 | SMN1; SMN2 (0.94) | MAOAMAOBSMN1; SMN2TP53EPHX1 | |
| SCHEMBL12644777 | 0.83 | MAOA (0.71) | MAOAMAOBSMN1; SMN2TP53EPHX1 | |
| SCHEMBL172819 | 0.82 | HPSE (0.72) | MAOAMAOBSMN1; SMN2TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113444024-A | Method for synthesizing polysubstituted ureas, thioureas, chiral ureas and thioureas compounds without catalyst and solvent | 安徽师范大学 | 2021-09-28 | — | — | CN | claimed |
| US-11834482-B2 | Agents modulating beta-catenin functions and methods thereof | FOG PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| CN-113444024-A | Method for synthesizing polysubstituted ureas, thioureas, chiral ureas and thioureas compounds without catalyst and solvent | 安徽师范大学 | 2021-09-28 | — | — | CN | disclosed |
| US-20200031811-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARM INT AG (CH) | 2020-01-30 | — | — | US | disclosed |
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2018-01-04 | — | — | US | disclosed |
| EP-3256217-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| CN-107428692-A | Substituted monoazanaphthalene derivatives and polyazanaphthalene derivatives and use thereof | 巴斯利尔药物国际股份公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-105007908-B | Use of agonists of formyl peptide receptor 2 for the treatment of skin diseases | 阿勒根公司 | 2017-10-03 | — | — | CN | disclosed |
| WO-2016128465-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128465-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| CN-101541781-A | Morpholino pyrimidine derivatives for the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2009-09-23 | — | — | CN | disclosed |
| EP-2057140-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-05-13 | — | — | EP | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| WO-2005030779-A2 | LAULIMALIDE ANALOGS WITH ANTI-CANCER ACTIVITITY | EISAI CO. LTD. (JP) | 2005-04-07 | — | — | WO | disclosed |
| US-6307067-B1 | Palladium and boron co-catalyzed addition of oxygen nucleophiles to vinyl epoxides | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2001-10-23 | — | — | US | disclosed |
| EP-1112240-A1 | THE ADDITION OF OXYGEN NUCLEOPHILES TO VINYL EPOXIDES | The Board of Trustees of The Leland S. Stanford Junior University (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000014033-A1 | THE ADDITION OF OXYGEN NUCLEOPHILES TO VINYL EPOXIDES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-03-16 | — | — | WO | disclosed |
| US-4444863-A | UREA COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1984-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | MAOA 4022/4885MAOB 3491/4885SMN1; SMN2 2807/4885 |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | LPXN, MLX, ZYX | MAOA 3503/4885MAOB 1081/4885SMN1; SMN2 2225/4885 |
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | CBR3, SCO2, CBR1 | MAOA 766/4885MAOB 877/4885SMN1; SMN2 3880/4885 |
| US-20200031811-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | CBR3, SCO2, CBR1 | MAOA 761/4885MAOB 877/4885SMN1; SMN2 3874/4885 |
| US-11834482-B2 | Agents modulating beta-catenin functions and methods thereof | CTNNB1, CTNNBL1, CTNNA1 | MAOA 4628/4885MAOB 4537/4885SMN1; SMN2 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.